Table 4.
A summary of radiological and pathological responses after neoadjuvant immunotherapy for patients with resectable non-small cell lung cancer.
| Radiological Response * | Pathological Response | ||||||
|---|---|---|---|---|---|---|---|
| Study | CR | PR | SD | PD | Major Pathological Response | Complete Pathological Response Primary Lesion | Complete Pathological Response Primary Lesion + Nodes |
| Rothschild [5] | 4/62 | 32/62 | 16/62 | 7/62 | 34/55 | 10/55 | 10/55 |
| Provencio [6] Roman [7] |
2/46 | 33/46 | 11/46 | 0 | 34/41 | 26/41 | 26/41 |
| Cascone [8] | 1/44 | 8/44 | 28/44 | 6/44 | 13/37 | 8/37 | - |
| Eicchorn [9] | 0 | 4/15 | 10/15 | 0 | 4/15 ^ | 2/15 | 2/15 |
| Tong [10] | - | - | - | 1/30 | 7/25 | 3/25 | 2/25 |
| Shu [11] | 0 | 19/30 | 9/30 | 2/30 | 17/29 | 10/29 | - |
| Bott [12] Forde [13] |
0 | 2/21 | 18/21 | 1/21 | 9/20 | 3/20 | 2/20 |
| Gao [14] | 0 | 8/40 | 28/40 | 4/40 | 15/37 | 6/37 | 3/37 |
| Yang [15] | 0 | 14/24 | 2/24 | 8/24 | - | 2/13 | - |
| Wang [16] | 21/72 | 47/72 | 3/72 | 1/72 | - | 21/72 | - |
| Shen [17] | 10/37 | 22/37 | 5/37 | 0 | 24/37 | 17/37 | 17/37 |
| Jiang [18] | 0 | 24/31 | 5/31 | 2/31 | 12/31 | 3/31 | - |
| Huang [19] | 0 | 8/25 | 16/25 | 1/25 | 9/24 | 1/24 | 1/24 |
| Duan [20] | 0 | 17/23 | 6/23 | 0 | 10/20 | 6/20 | - |
| Chen [21] | 0 | 6/12 | 6/12 | 0 | 9/12 ^ | 5/12 | - |
| Chen [22] | 0 | 17/35 | 18/35 | 0 | 26/35 | 18/35 | 16/35 |
| Total | 0.8% | 48.0% | 35.9% | 3.6% | 52.0% | 24.3% | 19.6% |
* According to Response Evaluation Criteria in Solid Tumors (RECIST) criteria: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease. ^ Major pathological response included all patients with <10% viable tumor.